MedTrace Logo

Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy

NCT06687876 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-07-10

No results posted yet for this study

Summary

The primary objective of this study is to investigate whether two weeks of metformin treatment can activate the tumour microenvironment in patients with stage II and III oesophageal adenocarcinomas.

Conditions

  • Oesophageal Adenocarcinoma
  • Tumor Microenvironment

Interventions

DRUG

Metformin

Twice a day 500mg of metfomrin orally (1000mg/day) during a 2-week period.

Sponsors & Collaborators

  • Cancer Center Amsterdam Research Foundation

    collaborator UNKNOWN

  • Amsterdam UMC, location VUmc

    lead OTHER

Principal Investigators

  • Sarah Derks, MD PhD · Amsterdam UMC, location VUmc

  • Hanneke W.M. van Laarhoven, MD, PhD · Amsterdam UMC, location VUmc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-09
Primary Completion
2026-12-31
Completion
2030-12-31
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06687876 on ClinicalTrials.gov